Regulatory FDA approves MSD’s Keytruda combinations for MIBC Pharmaceutical TechnologyThe FDA has approved two of MSD's anti-PD-1 therapies, Keytruda and Keytruda Qlex, along with Padcev, for adults with MIBC.OncologyRead full story pharminent July 13, 2026 (Last updated: July 13, 2026) Pharmaceutical Technology The FDA has approved two of MSD’s anti-PD-1 therapies, Keytruda and Keytruda Qlex, along with Padcev, for adults with MIBC. Oncology Read full story Post navigation Previous: Roche Scraps Two Ionis-Partnered Huntington’s Studies After Tominersen FailureNext: “Hub-and-spoke” drug manufacturing set to benefit from new FDA rule Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
